Search Results - "Pérez Fidalgo, José A"

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial by Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A, Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

“…The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive…”
Get full text

Concordance of genomic alterations between primary and recurrent breast cancer by Meric-Bernstam, Funda, Frampton, Garrett M, Ferrer-Lozano, Jaime, Yelensky, Roman, Pérez-Fidalgo, Jose A, Wang, Ying, Palmer, Gary A, Ross, Jeffrey S, Miller, Vincent A, Su, Xiaoping, Eroles, Pilar, Barrera, Juan Antonio, Burgues, Octavio, Lluch, Ana M, Zheng, Xiaofeng, Sahin, Aysegul, Stephens, Philip J, Mills, Gordon B, Cronin, Maureen T, Gonzalez-Angulo, Ana M

“…There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary…”
Get full text

Associations between Taste Perception Profiles and Empirically Derived Dietary Patterns: An Exploratory Analysis among Older Adults with Metabolic Syndrome by Gervis, Julie E, Fernández-Carrión, Rebeca, Chui, Kenneth K H, Ma, Jiantao, Coltell, Oscar, Sorli, Jose V, Asensio, Eva M, Ortega-Azorín, Carolina, Pérez-Fidalgo, José A, Portolés, Olga, Lichtenstein, Alice H, Corella, Dolores

“…Taste perception is a primary driver of food choices; however, little is known about how perception of all five tastes (sweet, salt, sour, bitter, umami)…”
Get full text

Non-Hodgkin's Lymphoma in Older People: Age Is Not Always an Adverse Prognostic Factor by Huerta, Angel Segura, Gómez-Codina, Jose, Pastor, Miguel, Gironés, Regina, Pérez-Fidalgo, José A., Díaz, Roberto

Get full text

Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: A prospective study by Lorenzo, María-José, Modesto, Manuel, Pérez, Javier, Bollo, Elena, Cordovilla, Rosa, Muñoz, Manuel, Pérez-Fidalgo, José A, Cases, Enrique

“…Background: Malignant pleural effusion is a clinical problem that impairs Quality of Life in patients with advanced malignancies. An indwelling pleural…”
Get full text

AKT Inhibition in Solid Tumors With AKT1 Mutations by Hyman, David M, Smyth, Lillian M, Donoghue, Mark T A, Westin, Shannon N, Bedard, Philippe L, Dean, Emma J, Bando, Hideaki, El-Khoueiry, Anthony B, Pérez-Fidalgo, José A, Mita, Alain, Schellens, Jan H M, Chang, Matthew T, Reichel, Jonathan B, Bouvier, Nancy, Selcuklu, S Duygu, Soumerai, Tara E, Torrisi, Jean, Erinjeri, Joseph P, Ambrose, Helen, Barrett, J Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P O, McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F, Chandarlapaty, Sarat, Solit, David B, Banerji, Udai, Baselga, José, Taylor, Barry S

“…Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an…”
Get full text

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy by Cruz, Cristina, Llop-Guevara, Alba, Garber, Judy E, Arun, Banu K, Pérez Fidalgo, José A, Lluch, Ana, Telli, Melinda L, Fernández, Cristian, Kahatt, Carmen, Galmarini, Carlos M, Soto-Matos, Arturo, Alfaro, Vicente, Pérez de la Haza, Aitor, Domchek, Susan M, Antolin, Silvia, Vahdat, Linda, Tung, Nadine M, Lopez, Rafael, Arribas, Joaquín, Vivancos, Ana, Baselga, José, Serra, Violeta, Balmaña, Judith, Isakoff, Steven J

“…This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with…”
Get full text

Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor by Carrillo-García, Jaime, Hindi, Nadia, Conceicao, Magda, Sala, María Ángeles, Ugalde, Aitziber, López-Pousa, Antonio, Bagué, Silvia, Sevilla, Isabel, Vicioso, Luis, Ramos, Rafael, Martínez-Trufero, Javier, Gómez Mateo, Ma Carmen, Cruz, Josefina, Hernández-León, Carmen Nieves, Redondo, Andrés, Mendiola, Marta, García, Jerónimo Martínez, Hernández, José Emilio, Álvarez, Rosa, Agra, Carolina, de Juan-Ferré, Ana, Valverde, Claudia, Cano, Juana María, Sande, Luis Miguel de, Pérez-Fidalgo, José A., Lavernia, Javier, Marcilla, David, Gutiérrez, Antonio, Moura, David S., Martín-Broto, Javier

“…Prognostic biomarkers remain necessary in sporadic desmoid tumor (DT) because the clinical course is unpredictable. DT location along with gene expression…”
Get full text

MicroRNA profile in very young women with breast cancer by Peña-Chilet, Maria, Martínez, Maria T, Pérez-Fidalgo, Jose A, Peiró-Chova, Lorena, Oltra, Sara S, Tormo, Eduardo, Alonso-Yuste, Elisa, Martinez-Delgado, Beatriz, Eroles, Pilar, Climent, Joan, Burgués, Octavio, Ferrer-Lozano, Jaime, Bosch, Ana, Lluch, Ana, Ribas, Gloria

“…Breast cancer is rarely diagnosed in very young women (35 years old or younger), and it often presents with distinct clinical-pathological features related to…”
Get full text

Analysis of Clinical Prognostic Factors for Survival and Time to Progression in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil—Based Chemotherapy by Yuste, Ana L., Aparicio, Jorge, Segura, Angel, López-Tendero, Pedro, Gironés, Regina, Pérez-Fidalgo, José A., Díaz, Roberto, Calderero, Verónica

“…Colorectal cancer (CRC) is one of the most common malignant tumors in adults. Twenty-five percent of patients are not amenable to surgical resection because…”
Get full text

Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer by Segura Huerta, Angel, Díaz-Beveridge, Roberto, Pérez-Fidalgo, José A, Calderero Aragón, Verónica, Pastor Borgoñón, Miguel, Aparicio Urtasun, Jorge, Montalar Salcedo, Joaquín

“…We undertook a prospective study to determine the feasibility, toxicity, response and survival rate of simultaneous chemotherapy (CT) and radiotherapy (RT) for…”
Get full text

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer by JESELSOHN, Rinath, YELENSKY, Roman, ARTEAGA, Carlos L, GILTNANE, Jennifer, BALKO, Justin M, CRONIN, Maureen T, JAROSZ, Mirna, SUN, James, HAWRYLUK, Matthew, LIPSON, Doron, OTTO, Geoff, ROSS, Jeffrey S, BUCHWALTER, Gilles, DVIR, Addie, SOUSSAN-GUTMAN, Lior, WOLF, Ido, RUBINEK, Tamar, GILMORE, Lauren, SCHNITT, Stuart, COME, Steven E, PUSZTAI, Lajos, STEPHENS, Philip, BROWN, Myles, FRAMPTON, Garrett, MILLER, Vincent A, MERIC-BERNSTAM, Funda, GONZALEZ-ANGULO, Ana Maria, FERRER-LOZANO, Jaime, PEREZ-FIDALGO, Jose A, CRISTOFANILLI, Massimo, GOMEZ, Henry

“…We undertook this study to determine the prevalence of estrogen receptor (ER) α (ESR1) mutations throughout the natural history of hormone-dependent breast…”
Get full text

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer by Pérez-Fidalgo, Jose A, Eroles, Pilar, Ferrer, Jaime, Bosch, Ana, Burgués, Octavio, Martínez, Francisco, Bermejo, Begoña, Lluch, Ana, González-Angulo, Ana M

“…Abstract Purpose Whether or not to biopsy the metastasis in recurrent breast cancer has become mired in controversy. Several studies have shown an important…”
Get full text

Pulmonary fibrosis induced by cyclophosphamide by Segura, A, Yuste, A, Cercos, A, Lopez-Tendero, P, Girones, R, Perez-Fidalgo, JA, Herranz, C

“…OBJECTIVE: To report a case of pulmonary fibrosis resulting from use of cyclophosphamide as chemotherapy to treat a patient with breast cancer. CASE SUMMARY:…”
Get full text

Abstract CT331: “BEECH”, a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s by Turner, Nicholas C., Oliveira, Mafalda, Armstrong, Anne, Sablin, Marie-Paule, Perez-Fidalgo, José A., Herebien, Sarah, Garcia-Murillas, Isaac, Johnson, Stan, Foxley, Andrew, Mahmood, Adnan, Lindemann, Justin P.

“…Background: The PI3K/AKT/MTOR pathway is frequently de-regulated in breast cancer. AZD5363 (AZD) is a potent selective inhibitor of AKT1-3. We report the…”
Get full text

High risk Ewing's sarcomas. Effectiveness and toxicity of a regimen designed for children and used in adults by Huerta, Ángel Segura, Pérez-Fidalgo, José A., Urtasun, Aparicio, López-Tendero, Pedro, Zotano, Ángel Guerrero, Salcedo, Joaquín Montalar

Get full text

Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial by Balmaña, Judit, Cruz, Cristina, Garber, Judy, Perez Fidalgo, Jose A, Lluch, Ana, Tung, Nadine, Antolin, Silvia, Fernandez, Cristian, Kahatt, Carmen, Szyldergemajn, Sergio, Soto Matos, Arturo, Extremera, Sonia, Baselga, Jose, Isakoff, Steven J

“…Background: Metastatic breast cancer (MBC) is a clinically heterogeneous disease in which selective approaches are needed to identify patients (pts) who will…”
Get full text